Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Urvi Aras"'
Autor:
Shan Jing, Yang Lin, Randy Dockens, David Marchisin, Bing He, Ihab G. Girgis, Anjaneya Chimalakonda, Bindu Murthy, Urvi Aras
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 12, Pp 3153-3164 (2023)
Abstract Introduction Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, blocks cytokine signaling involved in psoriasis pathogenesis. This ethnic-bridging study evaluated deucravacitinib pharmacokinetics, tolerability, and
Externí odkaz:
https://doaj.org/article/138681b5e9fe48568e696414c32c2790
Autor:
Bruno Sangro, Thomas Yau, Anthony B. El‐Khoueiry, Masatoshi Kudo, Yun Shen, Marina Tschaika, Amit Roy, Yan Feng, Ling Gao, Urvi Aras
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 8, Pp 1445-1457 (2023)
Abstract This analysis was conducted to inform dose selection of a combination of nivolumab plus ipilimumab for the treatment of sorafenib‐experienced patients with hepatocellular carcinoma (HCC). CheckMate 040 is an open‐label, multicohort, phas
Externí odkaz:
https://doaj.org/article/de9c65b4c41d434c935d3205ca0796a6
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 1, Pp 151-164 (2023)
Abstract This randomized, double‐blind, single‐ and multiple‐ascending dose study assessed the pharmacokinetics (PKs), pharmacodynamics, and safety of deucravacitinib (Sotyktu™), a selective and potent small‐molecule inhibitor of tyrosine k
Externí odkaz:
https://doaj.org/article/160d05762f494727925f54c50e945cba
Autor:
Bindu Murthy, Qihong Zhao, Takafumi Ide, Manoj Chiney, Huynh Yen Thanh Bach, Vineet Goti, Coburn Hobar, Urvi Aras
Publikováno v:
Lupus Science and Medicine, Vol 10, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/dd0bbd07c41a406194c485d98d89d279
Publikováno v:
Clinical and Translational Science. 16:151-164
This randomized, double-blind, single- and multiple-ascending dose study assessed the pharmacokinetics (PKs), pharmacodynamics, and safety of deucravacitinib (Sotyktu™), a selective and potent small-molecule inhibitor of tyrosine kinase 2, in 100 (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2be0ec27bb62065a61b01f695666b1c0
https://doi.org/10.1111/cts.13435
https://doi.org/10.1111/cts.13435
Autor:
Bruno Sangro, Thomas Yau, Anthony B. El‐Khoueiry, Masatoshi Kudo, Yun Shen, Marina Tschaika, Amit Roy, Yan Feng, Ling Gao, Urvi Aras
Publikováno v:
Clinical and Translational Science.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2200786b31ab0f488df7b6acf192a8f9
https://doi.org/10.1111/cts.13544
https://doi.org/10.1111/cts.13544
Autor:
Anjaneya, Chimalakonda, Shalabh, Singhal, Raymond, Darbenzio, Randy, Dockens, David, Marchisin, Subhashis, Banerjee, Ihab G, Girgis, John, Throup, Bing, He, Urvi, Aras, Bindu, Murthy
Publikováno v:
Clinical Pharmacology in Drug Development. 11:442-453
Deucravacitinib is a novel, oral, selective inhibitor of the intracellular signaling kinase tyrosine kinase 2. This phase 1, randomized, partially double-blind, 4-period crossover study in healthy adults was conducted to determine whether deucravacit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07ba45e3d729d1150d54b369b8bfcb9b
https://doi.org/10.1002/cpdd.1056
https://doi.org/10.1002/cpdd.1056
Autor:
Aitana Calvo, Marcelo Garrido, Iwona Lugowska, R. Donald Harvey, Matias Chacon, Federica Alessi, Heather E. Vezina, Sara Lonardi, Srivani Konduri, Jose Manuel Trigo, Urvi Aras, Trixia Camacho, Habte A. Yimer, Rastilav Bahleda, Sonia Dolfi, Kinjal Sanghavi, Christopher Jackson, Loes Latten-Jansen, Anne O'Donnell
Publikováno v:
Journal of Clinical Oncology. 39:2575-2575
2575 Background: Immunotherapy has transformed cancer survival expectations. Nivolumab (NIVO), a programmed death-1 inhibitor, is approved for intravenous (IV) administration across multiple cancers. BMS is developing a subcutaneous (SC) NIVO formula
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a5fe88b9c3ddcde2b6319a693e91a6d2
https://doi.org/10.1200/jco.2021.39.15_suppl.2575
https://doi.org/10.1200/jco.2021.39.15_suppl.2575
Autor:
Anthony W. Tolcher, Urvi Aras, Patricia D. Meholick, Thomas A. Puchalski, Honghui Zhou, C. H. Takimoto, Johann S. de Bono, Thomas J. McIntosh, Hugh M. Davis, Shobha Seetharam, Gerald J. Fetterly, Shahneen Sandhu
Publikováno v:
The Journal of Clinical Pharmacology. 53:1020-1027
The chemokine ligand 2 (CCL2) promotes angiogenesis, tumor proliferation, migration, and metastasis. Carlumab is a human IgG1 monoclonal antibody with high CCL2 binding affinity. Pharmacokinetic/pharmacodynamic data from 21 cancer patients with refra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e421ea8a57f299df3ba359c4722a6808
https://doi.org/10.1002/jcph.140
https://doi.org/10.1002/jcph.140
Publikováno v:
Biopharmaceutics & Drug Disposition. 34:98-106
The effect of phenethyl isothiocyanate (PEITC), a component of cruciferous vegetables, on the initiation and progression of cancer was investigated in a chemically induced estrogen-dependent breast cancer model. Breast cancer was induced in female Sp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1d8fa1cc555f2a336f495b6db71d86ba
https://doi.org/10.1002/bdd.1826
https://doi.org/10.1002/bdd.1826